Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for ...
The collaboration will make facility-level flexibility a standard capability across every InfraPartners AI data center ...
This hard freeze will affect a number of cold-sensitive, essential crops, including tomatoes, peppers, sweet corn, green beans, basil, and citrus plants — the last of which already face a losing ...
Researchers have identified a potential treatment strategy for Rett syndrome via alternative splicing modulation of the MECP2 gene.
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...
Recent studies show that coffee consumption’s role in gastrointestinal disorders, from GERD to cancer, is nuanced, underscoring the need for individual assessment.
Post hoc analyses of two Phase 2 trials examine the potential benefits of solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, ...
Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...
Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcineurin ...
Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...
New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results